Anti-Aging

FOXO4-DRI

Research Reagent · Laboratory Use Only

Quick Answer

How does FOXO4-DRI selectively target senescent cells?

FOXO4-DRI is a synthetic peptide that disrupts the FOXO4-p53 protein interaction maintaining senescent cells in a survival state. Releasing p53 triggers apoptosis selectively in senescent cells while sparing healthy cells. In aged mouse models, it restored fur density, kidney function, and exercise tolerance. It remains a preclinical research compound with no human trials.

PMID28340339↗DOI10.1016/j.cell.2017.02.031↗⟳ Reconstitution Calculator
Scientific AbstractPMID 28340339 · 2017

FOXO4-DRI (D-Retro-Inverso) is a synthetic peptide designed by Baar et al. at the Hubrecht Institute as a senolytic agent. It disrupts the FOXO4-p53 protein-protein interaction that maintains senescent cells in a survival state.

By releasing p53 to the cytoplasm, FOXO4-DRI selectively triggers apoptosis in senescent cells while sparing healthy cells. In aged mice, treatment produced restoration of fur density, improved kidney function, and increased exercise tolerance. Human clinical trials have not been conducted, and FOXO4-DRI remains a preclinical research compound.

Source:10.1016/j.cell.2017.02.031
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is FOXO4-DRI?

FOXO4-DRI is a synthetic peptide designed to selectively kill senescent cells — damaged cells that resist apoptosis and accumulate during aging, releasing inflammatory signals that damage surrounding tissue.

Mechanism of Action

FOXO4-DRI disrupts the FOXO4-p53 interaction that keeps senescent cells in a survival-favoring state. Releasing p53 to the cytoplasm triggers p53-mediated apoptosis selectively in senescent cells while leaving healthy cells unaffected.

Observed Laboratory Results

  • Restoration of fur density in aged mice
  • Improved renal function post-treatment in mouse models
  • Increased exercise tolerance in aged mice
  • Selective senescent cell apoptosis without toxicity to healthy cells

Research Status

FOXO4-DRI is a preclinical compound only. No human clinical trials have been registered or conducted as of 2026.

Clinical Research ParametersHuman Study Registry

No registered clinical trials or indexed human study data currently available for FOXO4-DRI via ClinicalTrials.gov or PubMed. This compound may be at preclinical or early research stages.

Search ClinicalTrials.gov ↗Search PubMed ↗
Research Compliance Notice

All data presented on this page is for laboratory research purposes only. FOXO4-DRI is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 28340339) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Anti-Aging Research Compounds

Epitalon
Epitalon, a naturally occurring tetrapeptide, is known for its anti-aging effects on mamma…
→
Humanin
BACKGROUND: Brain aging leads to structural changes, especially atrophy, which can result …
→
SS-31
Doxorubicin (DOX) is a widely used anticancer drug associated with severe cardiotoxicity p…
→
Thymulin
BACKGROUND: Development of neutralizing anti-factor [F]VIII antibodies (inhibitors) follow…
→
View all Anti-Aging compounds →